Search Within

Hamza Hashmi

Formats
  1. Meeting Abstract (41)
  2. Journal Article (14)
  3. Research Letter (3)
  4. Correspondence (2)
  5. Review (2)
  6. Editorial (1)
Groups
  1. Hematologic Malignancies, Division of (31)
  2. Center for Hematologic Malignancies (30)
  3. Department of Medicine (30)
  4. Bone Marrow Transplant (29)
  5. Survivorship Research (29)
  6. Myeloma (28)

More Groups

People
  1. Saad Usmani (30)
  2. Sridevi Rajeeve (30)
  3. Sham Mailankody (28)
  4. Heather Landau (26)
  5. Alexander Lesokhin (25)
  6. Carlyn Rose Tan (25)

More People

Years
  1. 2025 (11)
  2. 2024 (52)
Publications
  1. Blood (29)
  2. Clinical Lymphoma, Myeloma and Leukemia (16)
  3. Blood Cancer Journal (4)
  4. Blood Advances (3)
  5. European Journal of Haematology (2)
  6. Transplantation and Cellular Therapy (2)

More Publications

Publishers
  1. American Society of Hematology (32)
  2. Elsevier Inc. (18)
  3. Nature Publishing Group (4)
  4. John Wiley & Sons (3)
  5. American Society of Clinical Oncology (1)
  6. Biomed Central Ltd (1)

More Publishers

Results (63)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Comprehensive genomic sequencing predicts sub-optimal response to bispecific antibodies (BsAb) and chimeric antigen receptor T cells (CAR-T) in multiple myeloma (MM)
    Meeting Abstract

    Maclachlan, K.; Shekarkhand, T.; Farzana, T.; Costa, B.; Firestone, R.; Jurgens, E.; Rajeeve, S.; Hashmi, H.; Hassoun, H.; Shah, U.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Clinical outcomes of teclistamab among MajesTEC-1 eligible and ineligible population in the real-world setting for the treatment of relapsed/refractory multiple myeloma
    Meeting Abstract

    Tan, C.; Derkach, A.; Maclachlan, K.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U.; Rajeeve, S.; Hashmi, H.; Shah, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Impact of granulocyte colony-stimulating factor exposure on cytokine release syndrome during bispecific antibody initiation in relapsed/refractory multiple myeloma
    Meeting Abstract

    Wang, A.; Shekarkhand, T.; Derkach, A.; Nemirovsky, D.; Tan, C.; Hamadeh, I.; Firestone, R.; Jurgens, E.; Miller, K.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Real-world safety and efficacy of talquetamab for patients with heavily pretreated relapsed-refractory multiple myeloma
    Meeting Abstract

    Shaikh, H.; Lochner, J.; Friend, R.; Snyder, J.; Davis, J.; Patrus, G.; Dileo, R.; Ahmed, N.; Mewawalla, P.; poonsombudlert, K.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Prompt and profound responses with talquetamab in patients with heavily pretreated relapsed-refractory multiple myeloma - Another bridging therapy
    Meeting Abstract

    Shaikh, H.; Lochner, J.; Davis, J.; Snyder, J.; Friend, R.; Patrus, G.; DiLeo, R.; Mushtaq, M. U.; Green, K.; Mewawalla, P.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Incidence and clinical impact of acute kidney injury: A comparison of CAR T-cell and bispecific antibody therapies
    Meeting Abstract

    Nishimura, N.; Mailankody, S.; Nemirovsky, D.; Derkach, A.; Costa, B.; Farzana, T.; Jurgens, E.; Firestone, R.; Nath, K.; Chung, D.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Bispecific antibodies improve outcomes in patients with relapsed or refractory multiple myeloma after CAR-T cell therapy
    Meeting Abstract

    Merz, M.; Dima, D.; Hashmi, H.; Mueller, F.; Ahmed, N.; Rathje, K.; Davis, J.; Holderried, T.; Vucinik, V.; Kharbouti, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • CMV reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma
    Meeting Abstract

    Jurgens, E.; Shekarkhand, T.; Rueda, C.; Nemirovsky, D.; Derkach, A.; Firestone, R.; Miller, K.; Costa, B.; Rajeeve, S.; Lesokhin, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed/refractory multiple myeloma
    Meeting Abstract

    Costa, B.; Rajeeve, S.; Jurgens, E.; Nishimura, N.; Farzana, T.; Firestone, R.; Miller, K.; Lesokhin, A.; Shah, G.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Real-world safety and early efficacy of talquetamab in patients with heavily-pretreated relapsed/refractory multiple myeloma
    Meeting Abstract

    Costa, B.; Tan, C.; Shekarkhand, T.; Firestone, R.; Jurgens, E.; Miller, K.; Lesokhin, A.; Shah, G.; Korde, N.; Rajeeve, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save